Overview

Rasburicase for Treatment of Hyperuricemia in Children and Adolescence Patients With Tumor Lysis Syndrome

Status:
Completed
Trial end date:
2004-01-01
Target enrollment:
Participant gender:
Summary
To provide treatment opportunity to children and adolescent patients with hematologic malignancies by supplying the delayed marketed product and also to observe the efficacy and safety of rasburicase used in the treatment of hyperuricemia
Phase:
Phase 4
Details
Lead Sponsor:
Sanofi
Treatments:
Rasburicase